FindTrial
Sign In

Predicting liver function using multi-modality ultrasound

Predicting liver function using multi-modality ultrasound

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-DDD-17013186
Enrollment
Unknown
Registered
2017-10-31
Start date
2017-12-01
Completion date
Unknown
Last updated
2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver dysfunction

Interventions

patients&#32
Gold Standard:Liver fibrosis and necroinflammatory activity were evaluated according to the METAVIR scoring system. The severity of the liver fibrosis was expressed: F0, no fibrosis
F1, portal fibrosis with no septa
F2, portal fibrosis with few septa
F3, bridging fibrosis with many septa
and F4, cirrhosis.
Index test:Age,&#32
sex,&#32
weight&#32
and&#32
height&#32
were&#32
recorded.&#32
Venous&#32
blood&#32
samples&#32
obtained&#32
after&#32
the&#32

Sponsors

Department of Medical Ultrasonics, The First Affiliated Hospital of Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-80 years old; 2. Agreement of performance of SWE,ASQ,NFI,CEUS and liver biopsy; 3. Capable to complete the corresponding treatment, plan follow-up, and laboratory examination;Inclusion criteria: 1. Age 18-80 years old; 2. Agreement of performance of SWE,ASQ,NFI,CEUS and liver biopsy; 3. Capable to complete the corresponding treatment, plan follow-up, and laboratory examination;Inclusion criteria: 1. Age 18-80 years old; 2. Agreement of performance of SWE,ASQ,NFI,CEUS and liver biopsy; 3. Capable to complete the corresponding treatment, plan follow-up, and laboratory examination;Inclusion criteria: 1. Age 18-80 years old; 2. Agreement of performance of SWE,ASQ,NFI,CEUS and liver biopsy; 3. Capable to complete the corresponding treatment, plan follow-up, and laboratory examination;Inclusion criteria: 1. Age 18-80 years old; 2. Agreement of performance of SWE,ASQ,NFI,CEUS and liver biopsy; 3. Capable to complete the corresponding treatment, plan follow-up, and laboratory examination

Exclusion criteria

Exclusion criteria: 1. Patients with severe heart and lung disease; 2. Pregnant and lactating women; 3. contraindications in CEUS;Exclusion criteria: 1. Patients with severe heart and lung disease; 2. Pregnant and lactating women; 3. contraindications in CEUS;Exclusion criteria: 1. Patients with severe heart and lung disease; 2. Pregnant and lactating women; 3. contraindications in CEUS;Exclusion criteria: 1. Patients with severe heart and lung disease; 2. Pregnant and lactating women; 3. contraindications in CEUS;Exclusion criteria: 1. Patients with severe heart and lung disease; 2. Pregnant and lactating women; 3. contraindications in CEUS

Design outcomes

Primary

MeasureTime frame
Young's modulus;Liver and kidney perfusion ratio;FD ratio;—

Countries

China

Contacts

Public ContactWei Wang;Wei Wang;Wei Wang;Wei Wang;Wei Wang ;;;;

The First Affiliated Hospital of Sun Yat-Sen University;The First Affiliated Hospital of Sun Yat-Sen University;The First Affiliated Hospital of Sun Yat-Sen University;The First Affiliated Hospital of Sun Yat-Sen University;The First Affiliated Hospital of Sun Yat-Sen University

wangw73@mail.sysu.edu.cn;wangw73@mail.sysu.edu.cn;wangw73@mail.sysu.edu.cn;wangw73@mail.sysu.edu.cn;wangw73@mail.sysu.edu.cn+86 18218227118;+86 18218227118;+86 18218227118;+86 18218227118;+86 18218227118

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026